Intrapleural administration of a serotype 5 adeno-associated virus coding for α1-antitrypsin mediates persistent, high lung and serum levels of α1-antitrypsin

Bishnu De, Adriana Heguy, Philip L. Leopold, Nabil Wasif, Robert J. Korst, Neil R. Hackett, Ronald Crystal

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

α1-Antitrypsin (α1AT) is a serine proteinase inhibitor that protects the lung from degradation by neutrophil proteases. In α1AT deficiency, an autosomal recessive disorder resulting from mutations in the α1AT (approved symbol SERPINA1) gene, serum α1AT levels of <570 μg/ml are associated with development of emphysema. Adeno-associated virus (AAV) serotype 2 (AAV2) vectors expressing α1AT administered intramuscularly or intravenously mediate sustained serum levels of α1AT in experimental animals. Since the lung is only 2% of the body weight, AAV vector delivery to the muscle or liver is inefficient, as most of the α1AT does not reach the lung. The present study evaluates AAV2- and AAV5-mediated delivery of human α1AT (hα1AT) to C57BL/6 mice using the intrapleural space as a platform for local production of α1AT. Intrapleural administration of either an AAV5-hα1AT or an AAV2-hα1AT vector achieves higher lung and serum levels of α1AT than intramuscular delivery. AAV5-mediated serum and lung α1AT levels were 10-fold higher than those achieved by AAV2 delivery via either route. The diaphragm, lung, and heart are the major sites of transgene expression following intrapleural administration of an AAV5 reporter vector. At 40 weeks postadministration, intrapleural administration of the AAV5-hα1AT vector mediated serum α1AT levels of 900 ± 50 μg/ml, 1.6-fold higher than the accepted therapeutic level of 570 μg/ml. In the context that the pleura is a safe site for administration, intrapleural administration using AAV5 vectors may represent an attractive gene therapy strategy for α1AT deficiency in humans.

Original languageEnglish
Pages (from-to)1003-1010
Number of pages8
JournalMolecular Therapy
Volume10
Issue number6
DOIs
Publication statusPublished - 1 Dec 2004
Externally publishedYes

Fingerprint

Dependovirus
Lung
Serum
Serine Proteinase Inhibitors
Pleura
Emphysema
Diaphragm
Transgenes
Inbred C57BL Mouse
Genetic Therapy
Serogroup
Neutrophils
Peptide Hydrolases
Body Weight
Muscles
Mutation
Liver
Genes

ASJC Scopus subject areas

  • Molecular Medicine
  • Molecular Biology
  • Genetics
  • Pharmacology
  • Drug Discovery

Cite this

Intrapleural administration of a serotype 5 adeno-associated virus coding for α1-antitrypsin mediates persistent, high lung and serum levels of α1-antitrypsin. / De, Bishnu; Heguy, Adriana; Leopold, Philip L.; Wasif, Nabil; Korst, Robert J.; Hackett, Neil R.; Crystal, Ronald.

In: Molecular Therapy, Vol. 10, No. 6, 01.12.2004, p. 1003-1010.

Research output: Contribution to journalArticle

De, Bishnu ; Heguy, Adriana ; Leopold, Philip L. ; Wasif, Nabil ; Korst, Robert J. ; Hackett, Neil R. ; Crystal, Ronald. / Intrapleural administration of a serotype 5 adeno-associated virus coding for α1-antitrypsin mediates persistent, high lung and serum levels of α1-antitrypsin. In: Molecular Therapy. 2004 ; Vol. 10, No. 6. pp. 1003-1010.
@article{6c7269bd70604e6484ea409a1b2d8633,
title = "Intrapleural administration of a serotype 5 adeno-associated virus coding for α1-antitrypsin mediates persistent, high lung and serum levels of α1-antitrypsin",
abstract = "α1-Antitrypsin (α1AT) is a serine proteinase inhibitor that protects the lung from degradation by neutrophil proteases. In α1AT deficiency, an autosomal recessive disorder resulting from mutations in the α1AT (approved symbol SERPINA1) gene, serum α1AT levels of <570 μg/ml are associated with development of emphysema. Adeno-associated virus (AAV) serotype 2 (AAV2) vectors expressing α1AT administered intramuscularly or intravenously mediate sustained serum levels of α1AT in experimental animals. Since the lung is only 2{\%} of the body weight, AAV vector delivery to the muscle or liver is inefficient, as most of the α1AT does not reach the lung. The present study evaluates AAV2- and AAV5-mediated delivery of human α1AT (hα1AT) to C57BL/6 mice using the intrapleural space as a platform for local production of α1AT. Intrapleural administration of either an AAV5-hα1AT or an AAV2-hα1AT vector achieves higher lung and serum levels of α1AT than intramuscular delivery. AAV5-mediated serum and lung α1AT levels were 10-fold higher than those achieved by AAV2 delivery via either route. The diaphragm, lung, and heart are the major sites of transgene expression following intrapleural administration of an AAV5 reporter vector. At 40 weeks postadministration, intrapleural administration of the AAV5-hα1AT vector mediated serum α1AT levels of 900 ± 50 μg/ml, 1.6-fold higher than the accepted therapeutic level of 570 μg/ml. In the context that the pleura is a safe site for administration, intrapleural administration using AAV5 vectors may represent an attractive gene therapy strategy for α1AT deficiency in humans.",
author = "Bishnu De and Adriana Heguy and Leopold, {Philip L.} and Nabil Wasif and Korst, {Robert J.} and Hackett, {Neil R.} and Ronald Crystal",
year = "2004",
month = "12",
day = "1",
doi = "10.1016/j.ymthe.2004.08.022",
language = "English",
volume = "10",
pages = "1003--1010",
journal = "Molecular Therapy",
issn = "1525-0016",
publisher = "Nature Publishing Group",
number = "6",

}

TY - JOUR

T1 - Intrapleural administration of a serotype 5 adeno-associated virus coding for α1-antitrypsin mediates persistent, high lung and serum levels of α1-antitrypsin

AU - De, Bishnu

AU - Heguy, Adriana

AU - Leopold, Philip L.

AU - Wasif, Nabil

AU - Korst, Robert J.

AU - Hackett, Neil R.

AU - Crystal, Ronald

PY - 2004/12/1

Y1 - 2004/12/1

N2 - α1-Antitrypsin (α1AT) is a serine proteinase inhibitor that protects the lung from degradation by neutrophil proteases. In α1AT deficiency, an autosomal recessive disorder resulting from mutations in the α1AT (approved symbol SERPINA1) gene, serum α1AT levels of <570 μg/ml are associated with development of emphysema. Adeno-associated virus (AAV) serotype 2 (AAV2) vectors expressing α1AT administered intramuscularly or intravenously mediate sustained serum levels of α1AT in experimental animals. Since the lung is only 2% of the body weight, AAV vector delivery to the muscle or liver is inefficient, as most of the α1AT does not reach the lung. The present study evaluates AAV2- and AAV5-mediated delivery of human α1AT (hα1AT) to C57BL/6 mice using the intrapleural space as a platform for local production of α1AT. Intrapleural administration of either an AAV5-hα1AT or an AAV2-hα1AT vector achieves higher lung and serum levels of α1AT than intramuscular delivery. AAV5-mediated serum and lung α1AT levels were 10-fold higher than those achieved by AAV2 delivery via either route. The diaphragm, lung, and heart are the major sites of transgene expression following intrapleural administration of an AAV5 reporter vector. At 40 weeks postadministration, intrapleural administration of the AAV5-hα1AT vector mediated serum α1AT levels of 900 ± 50 μg/ml, 1.6-fold higher than the accepted therapeutic level of 570 μg/ml. In the context that the pleura is a safe site for administration, intrapleural administration using AAV5 vectors may represent an attractive gene therapy strategy for α1AT deficiency in humans.

AB - α1-Antitrypsin (α1AT) is a serine proteinase inhibitor that protects the lung from degradation by neutrophil proteases. In α1AT deficiency, an autosomal recessive disorder resulting from mutations in the α1AT (approved symbol SERPINA1) gene, serum α1AT levels of <570 μg/ml are associated with development of emphysema. Adeno-associated virus (AAV) serotype 2 (AAV2) vectors expressing α1AT administered intramuscularly or intravenously mediate sustained serum levels of α1AT in experimental animals. Since the lung is only 2% of the body weight, AAV vector delivery to the muscle or liver is inefficient, as most of the α1AT does not reach the lung. The present study evaluates AAV2- and AAV5-mediated delivery of human α1AT (hα1AT) to C57BL/6 mice using the intrapleural space as a platform for local production of α1AT. Intrapleural administration of either an AAV5-hα1AT or an AAV2-hα1AT vector achieves higher lung and serum levels of α1AT than intramuscular delivery. AAV5-mediated serum and lung α1AT levels were 10-fold higher than those achieved by AAV2 delivery via either route. The diaphragm, lung, and heart are the major sites of transgene expression following intrapleural administration of an AAV5 reporter vector. At 40 weeks postadministration, intrapleural administration of the AAV5-hα1AT vector mediated serum α1AT levels of 900 ± 50 μg/ml, 1.6-fold higher than the accepted therapeutic level of 570 μg/ml. In the context that the pleura is a safe site for administration, intrapleural administration using AAV5 vectors may represent an attractive gene therapy strategy for α1AT deficiency in humans.

UR - http://www.scopus.com/inward/record.url?scp=10344235189&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=10344235189&partnerID=8YFLogxK

U2 - 10.1016/j.ymthe.2004.08.022

DO - 10.1016/j.ymthe.2004.08.022

M3 - Article

VL - 10

SP - 1003

EP - 1010

JO - Molecular Therapy

JF - Molecular Therapy

SN - 1525-0016

IS - 6

ER -